ClinicalTrials.gg
Active, not recruitingNCT06895343Updated Mar 2, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

A Phase 1 interventional study of ABBV-701 and Placebo in Healthy Volunteer, sponsored by AbbVie. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-701
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight is ≥ 35 kg and is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth's decimal.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead
  • Part 2 and Part 4 only:

For Japanese Participants:

--Participant must be first or second-generation Japanese parentage (both parents of Japanese descent), residing outside of Japan. Participants must be in general good health and maintain a typical Japanese lifestyle, including consuming a typical Japanese diet.

Han Chinese Participants:

--Participant must be first or second-generation Han Chinese of full Chinese parentage (both parents of Han Chinese descent), residing outside of China. Participants must be in general good health and maintain a typical Chinese lifestyle, including consuming a typical Chinese diet.

Exclusion criteria

Exclusion Criteria:

  • History of any cardiovascular, respiratory (except mild asthma as a child), renal, endocrine, hepatic, gastrointestinal, hematologic, or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Part 1: Group 1 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose A or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 1: Group 2 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose B or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 1: Group 3 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose C or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 1: Group 4 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose D or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 1: Group 5 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose E or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 2: Group 6 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose E or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 2: Group 7 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose E or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 3: Group 8 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose C or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 3: Group 9 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose E or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 3: Group 10 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose F or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 4: Group 11 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose F or placebo.

    Drug: ABBV-701 · Drug: Placebo

  • Experimental
    Part 4: Group 12 ABBV-701 or Placebo

    Participants will receive a single dose of either ABBV-701 Dose F or placebo.

    Drug: ABBV-701 · Drug: Placebo

Interventions

  • Subcutaneous

  • DrugPlacebo

    Subcutaneous

  • IV Infusion

  • DrugPlacebo

    IV infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 47 weeks

  2. Maximum Plasma Concentration (Cmax) of ABBV-701

    Cmax of ABBV-701

    Time frame: Up to approximately 47 weeks

  3. Time to Cmax (Tmax) of ABBV-701

    Tmax of ABBV-701

    Time frame: Up to approximately 47 weeks

  4. Apparent terminal phase elimination rate constant (β) of ABBV-701

    (β) of ABBV-701

    Time frame: Up to approximately 47 weeks

  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-701

    (t1/2) of ABBV-701

    Time frame: Up to approximately 47 weeks

  6. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-701

    AUCt of ABBV-701

    Time frame: Up to approximately 47 weeks

  7. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-701

    AUCinf of ABBV-701

    Time frame: Up to approximately 47 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Mar 26, 2025
StartActual
Apr 3, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06895343
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Apr 3, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Mar 2, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-701

Start the discussion